Skip to Main content Skip to Navigation
Journal articles

RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine

Abstract : Respiratory syncytial virus (RSV) is the leading cause of acute respiratory infections in children, yet no vaccine is available. The sole licensed preventive treatment against RSV is composed of a monoclonal neutralizing antibody (palivizumab), which targets a conformational epitope located on the fusion protein (F). Palivizumab reduces the burden of bronchiolitis but does not prevent infection. Thus, the development of RSV vaccines remains a priority.We previously evaluated nanorings formed by RSV nucleoprotein (N) as an RSV vaccine, as well as an immunostimulatory carrier for heterologous antigens. Here we linked the palivizumab-targeted epitope (called FsII) to N, to generate N-FsII-nanorings. Intranasal N-FsII immunization elicited anti-F antibodies in mice that were non-neutralizing in vitro. Nevertheless, RSV-challenged animals were better protected against virus replication than mice immunized with N-nanorings, especially in the upper airways. In conclusion, an N-FsII-focused vaccine is an attractive candidate combining N-specific cellular immunity and F-specific antibodies for protection
Document type :
Journal articles
Complete list of metadata

Cited literature [29 references]  Display  Hide  Download
Contributor : Migration Prodinra <>
Submitted on : Tuesday, May 26, 2020 - 10:48:14 PM
Last modification on : Monday, September 13, 2021 - 7:32:01 AM


Files produced by the author(s)



Pierre Louis Hervé, Charlotte Deloizy, Delphyne Descamps, Marie-Anne Rameix Welti, Jenna Fix, et al.. RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine. Nanomedicine: Nanotechnology, Biology and Medicine, Elsevier, 2017, 13 (2), pp.411-420. ⟨10.1016/j.nano.2016.08.006⟩. ⟨hal-02628338⟩



Record views


Files downloads